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Abstract. We evaluated lymph node aspiration (LNA) as a simple diagnostic procedure for visceral leishmaniasis
(VL). Lymph node aspiration was compared with the direct agglutination test (DAT) using a diagnostic titer  1:6,400
in 7,880 suspected VL patients in eastern Sudan. Compared with DAT, LNA had a sensitivity of 65.1% (95% confidence
interval  63.5–66.6%). Parasite density in LNA correlated strongly with DAT titers (P < 0.0001), and low parasite
density accounted for 78.1% of positive LNA results with DAT titers < 1:6,400 (n  782). Risk factors predictive of a
positive LNA result were an age of 1–29 years, male sex, a hemoglobin level < 10.0 g/dL, a DAT titer  1:800, and a
location with a higher prevalence of VL. Lymph node and splenic aspirations were similarly accurate as tests of cure after
treatment of 50 VL patients in southern Sudan. Pre-treatment LNA results were negative in 20 cases of severe post
kala-azar dermal leishmaniasis.
INTRODUCTION
Visceral leishmaniasis (VL or kala-azar) is a parasitic dis-
ease that clinically resembles a number of other infections. It
is usually fatal if undiagnosed and untreated, but if treated
usually leads to life-long immunity. This disease is classically
diagnosed by demonstrating parasites in smears from spleen
or bone marrow, and occasionally in buffy coat, lymph nodes,
or liver biopsy specimens. Because of concerns of fatal intra-
abdominal hemorrhage, splenic aspiration is sometimes
avoided in remote rural settings.
1 Bone marrow aspiration,
although safe, is a tedious and sometimes painful procedure
and requires costly disposable bone marrow needles.
2,3
The high prevalence of generalized lymphadenopathy
among Sudanese VL patients suggests lymph node aspiration
(LNA) might be useful in establishing a parasitologic diagno-
sis of VL.
4,5 The splenomegaly of VL disappears at the end of
treatment in 78% of Sudanese patients.
6 Because 90% of
patients will still have palpable lymph nodes,
4 LNA might
also be useful in assessing initial parasite clearance. However,
parasites are reportedly found in groin lymph nodes in some
patients with post–kala-azar dermal leishmaniasis (PKDL),
3
which might give a false impression that the patient had VL.
Among other serodiagnostic tests, the direct agglutination
test (DAT) has been extensively used under field conditions
to diagnose VL.
7,8 A meta-analysis including 30 studies on
DAT showed a sensitivity of 94.8% and a specificity of 85.9%
in clinically suspected VL patients.
9
To establish the usefulness of LNA in the diagnosis of VL,
we analyzed clinical and laboratory data collected from sus-
pected cases of VL seen during a 43-month period at the
Médecins Sans Frontières (MSF)–Holland VL treatment cen-
ters in Gedaref State in eastern Sudan. We report validity
estimates of LNA in comparison to DAT. We also examined
biologic and environmental factors that could predict the re-
sults of LNA.
Additionally, in the MSF-Holland VL treatment center in
Jonglei Province in southern Sudan, we sought to establish
whether LNA might provide useful results when used as a test
of parasite clearance at the end of treatment for VL. We
compared the performance of LNA and splenic aspiration
(SA) in VL patients who received their first course of treat-
ment. We also performed LNA in patients with severe PKDL
before treatment to assess the presence of parasites in such
aspirates.
MATERIALS AND METHODS
LNA versus DAT in patients suspected of having VL.
Study area. Visceral leishmaniasis is endemic in the southern
part of Gedaref State in eastern Sudan. This is a remote but
fertile farming region characterized by woodlands of Acacia
seyal and Balanites aegyptica, soft black soil, and dry savan-
nah climate with a short rainy season (July–October). Leish-
mania donovani is the parasite and Phlebotomus orientalis is
the vector responsible for VL transmission in this region.
3
Médecins Sans Frontières VL treatment centers. The Um
Elkheir and Kassab centers in eastern Sudan were run by
MSF to provide treatment for VL for a rural population of
approximately 500,000. The medical department of (MSF)-
Holland reviewed and approved the study.
Study population. All patients clinically suspected of hav-
ing VL who came to the MSF treatment centers at Um
Elkheir and Kassab from February 1998 to August 2001 were
included in the study. We included individuals who had not
been previously treated for VL and who had a fever for > 2
weeks with either splenomegaly or lymphadenopathy. We
provided diagnosis and treatment of malaria while investigat-
ing for possible VL. Patients who were previously treated for
VL were excluded because the DAT does not differentiate
between past or current VL. Similarly, patients with PKDL
were excluded.
Direct agglutination test. Aqueous Leishmania antigen was
obtained from the Prince Leopold Institute of Tropical Medi-
cine (Antwerp, Belgium) and the Royal Tropical Institute
(Amsterdam, The Netherlands). Each batch of antigen was
standardized with freeze-dried positive controls of known ti-
ters. Whole blood samples were collected by finger prick on
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689Whatman (Brentford, United Kingdom) 3 filter paper and
left to air-dry. Briefly, 5-mm disks (5 L of blood) were
punched from the filter paper and placed in microtiter plates
containing 96 V-shaped wells. Samples were eluted and seri-
ally diluted to titers  1:102,400. After overnight incubation
at ambient temperature, plates were read for agglutination.
The titer recorded was the highest dilution at which aggluti-
nation was visible.
Lymph node aspiration. The LNA was performed by our
laboratory technicians; the entire procedure was performed in
< 1 minute without local anesthesia. Aspirations produced a
similar degree of discomfort as that from taking a blood
sample. The patient lay on a local bed (angareb) in a screened
area of the laboratory. The overlying skin was cleaned and
the largest palpable inguinal lymph node was held firmly be-
tween thumb and index fingers while a 21-gauge 1.25-inch
hypodermic needle was inserted. Lymph was encouraged to
flow up the needle by twirling it and gently milking the lymph
node. The needle was then withdrawn with the hub being
sealed by the index finger. The aspirate was expelled onto a
glass slide, smeared, air-dried, fixed with 100% methanol, and
stained with Giemsa.
The density of L. donovani parasites was determined ac-
cording to the method of Chulay and Bryceson.
1 The grades
used were: Grade 6: > 100 amastigotes/high-power field
(HPF); Grade 5: 10–100 amastigotes/HPF; Grade 4: 1–10
amastigotes/HPF; Grade 3: 1–10 amastigotes/10 HPFs; Grade
2: 1–10 amastigotes/100 HPFs; Grade 1: 1–10 (amastigotes/
1,000 HPFs; Negative: no amastigotes seen in 1,000 HPFs.
Diagnostic protocol. Figure 1 shows the diagnostic protocol
we used. All cases suspected of having primary VL cases
underwent the DAT. A DAT titer  1:6,400 in patients sat-
isfying the VL clinical case definition was regarded as diag-
nostic.
10 Those with borderline DAT titers (1:800–1:3,200)
underwent further testing by LNA. Patients suspected of hav-
ing VL who appeared acutely unwell were further tested to
obtain a diagnosis as quickly as possible: they underwent
LNA on the same day as the DAT, with repeat LNA and
DAT after 1 day and 1 week, respectively. Patients suspected
of having VL with a negative DAT titer ( 1:400) were evalu-
ated to obtain alternative diagnoses. On average, it took two
working days for the DAT results to be obtained. Diagnostic
procedures were always explained and verbal consent was
obtained from the patients or their guardians. Laboratories in
each treatment center followed standardized operating pro-
cedures and were subject to routine periodic quality control
assessments by MSF.
Post-treatment LNA versus SA in VL patients. Primary VL
patients initially diagnosed by DAT or aspirate underwent
simultaneous lymph node and spleen aspiration to assess
parasite clearance at the end of their treatment for VL at the
MSF center in Lankien, Jonglei province in southern Sudan.
Post-treatment aspirates were performed on day 28 of treat-
ment with sodium stibogluconate (20 mg/kg).
To perform splenic aspiration, a 21-gauge hypodermic
needle attached to a 5-mL syringe was inserted in the midline
of the anterior surface of the spleen. The needle is inserted
quickly to its full depth (1.25 inches) into the spleen while a
vacuum is being created and maintained by pulling the
plunger back. The needle is removed rapidly form the spleen.
The (scanty) aspirate is expressed onto a slide, smeared, air-
dried, fixed with 100% methanol, and stained with Giemsa.
Slides were independently assessed and parasites on LNAs
and SAs were quantified as per the method of Chulay and
Bryceson.
1
Pre-treatment LNA in PKDL patients. Post kala-azar der-
mal leishmaniasis was diagnosed on clinical grounds by a re-
cent history of VL and a classic rash. Twenty patients with
severe PKDL who came to the MSF VL treatment center in
Lankien, Jonglei Province in southern Sudan agreed to un-
dergo LNA before starting treatment.
Data processing and analysis. Laboratory data for patients
suspected of having VL were routinely recorded in ledgers.
Data included date, treatment center, name, age, sex, hemo-
globin concentration, DAT titer, and parasite grade on LNA.
These data were entered into Microsoft (Redmond, WA) Ex-
cel. Range and consistency checks were performed and a
coding scheme was subsequently developed. Missing values
were recoded, the database was cleaned and saved as a tab-
delimited text file, and transferred into STATA version 7.0
(STAT Corp., College Station, TX) for analysis. We also col-
lected data from laboratory records in southern Sudan that
contained information on post-treatment simultaneous SAs
and LNAs, as well as results of pre-treatment LNAs in PKDL
patients.
The chi-square test was used to assess the association be-
tween categorical variables. A logistic regression model was
constructed to predict which suspected VL cases were more
likely to have positive LNA results. We constructed a hierar-
chical order for variables to allow for proper control of distant
and proximate potential confounders.
11 Age, sex, season,
treatment center, hemoglobin level, and DAT titer were se-
rially fitted into the regression model. The Mantel-Haenzel
odds ratios with 95% confidence intervals (CIs) were used to
express the strength of associations between biologic and en-
vironmental factors and results of LNA.
FIGURE 1. Diagnostic flow chart for cases suspected of having
visceral leishmaniasis (VL) seen at the Médecins Sans Frontières–
Holland treatment centers in eastern Sudan.
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LNA versus DAT in patients suspected of having VL.
Overall, 22,540 patients clinically suspected of having VL un-
derwent the DAT during the study period. A total of 7,880
subjects underwent simultaneous DAT and LNA. If either
DAT or LNA was repeated, only the first result was analyzed.
A total of 9,328 subjects underwent LNA. Of this group,
1448 subjects underwent LNA without DAT because of an
interruption of DAT supplies to the field sites. Poor-quality
lymph node samples were obtained in 8 (< 0.1%) of 9,328
LNAs and these were excluded from further analysis. Using a
cut-off DAT titer  1:6,400 (Table 1), validity estimates of
LNA among 7,880 patients undergoing simultaneous DAT
and LNA testing yielded a sensitivity of 65.1% (95% CI 
63.5–66.6%).
Table 2 shows a strong correlation between parasite load
on LNAs and the corresponding DAT titers (P < 0.0001, by
chi-square test for trend). To provide larger groups, we sim-
plified parasite scores to low density (grades 1 and 2), medium
density (grades 3 and 4), and high density (grades 5 and 6). A
total of 782 patients had positive LNAs but their correspond-
ing DAT titers were < 1:6,400. Overall, this group accounted
for 25.3% (782 of 3,092) of all positive LNA results. Further
breakdown of positive LNA results with DAT titers < 1:6,400
showed that a low parasite density accounted for 78.1%
(611 of 782) of the results, medium density accounted for
21.0% (164 of 782), and high density accounted for 0.9% (7 of
782).
Age, sex, hemoglobin level, season, location of treatment
center, and DAT titer were strongly associated with a positive
outcome of LNA (P < 0.0001, by chi-square test; data avail-
able upon request). Table 3 shows the results of multivariate
analysis using a hierarchical model for these variables. Male
sex and young age were linked to increased odds of a positive
LNA result. The odds of obtaining a positive LNA result
correlated with severity of anemia. We found a strong posi-
tive correlation between DAT titer and the likelihood of ob-
taining a positive LNA result. The LNA results were more
likely to be positive in Um Elkheir than in Kassab. Less
lymph node aspirates were positive in April–June compared
with our baseline period of July–September.
Post-treatment LNA versus SA in VL patients. Fifty pri-
mary VL patients in southern Sudan underwent simultaneous
LNA and SA to assess parasite clearance at the end of their
treatment for VL. Overall, both LNA and SA identified 43
patients as negative and 6 patients as positive for Leishmania
parasites. However, in one case, the SA result was negative
but a corresponding LNA result was positive with grade 3
parasite density.
Pre-treatment LNA in PKDL patients. No parasites were
found in lymph node aspirates obtained from 20 patients with
severe PKDL in southern Sudan.
DISCUSSION
Lymph node aspiration has rarely been studied as a method
for diagnosing VL. In a series of 30 confirmed Sudanese VL
cases,
2 Leishmania parasites were found in 30 of 30 LNAs. In
two cases, parasites were found in LNAs and bone marrow
aspirates (BMAs) but not in SAs, and in one case they were
found in LNAs and SAs but not in BMAs. In another series
of confirmed Kenyan VL patients,
12 parasites were found in
20 of 31 LNAs, 18 of 19 liver biopsy samples, and 39 of 40
SAs. When compared with SAs in the Sudan, two small stud-
ies found LNAs to have low sensitivities of 56% (n  19) and
54% (n  87), respectively.
13,14
In our experience, LNAs produced good quality material in
> 99.9% of the subjects. We used the DAT as the reference
test in this study, although it provides only indirect evidence
of the parasite. The slight risk of causing bleeding by unnec-
essary SAs made it difficult for us to use SAs as the gold
standard against which to evaluate LNAs. Furthermore, pa-
tients who underwent both LNAs and SAs to establish a di-
agnosis of VL were inevitably those in whom the LNA had
been done first and had failed to demonstrate parasites. Di-
agnostic SAs were rarely done in our centers and only when
all other results were inconclusive (SAs were performed in
353 of 22,540 VL suspects seen over a period of 43 months in
eastern Sudan).
When LNA was compared with the DAT, LNA had a sen-
sitivity of 65%. It is important to note that we gathered these
data in an operational setting where the prevalence of VL was
approximately 45% among our clinical suspects. Our diagnos-
tic algorithm contained an inherent bias that led to underes-
timating the sensitivity of LNA: 22,540 subjects underwent
DAT whereas only 9,328 subjects underwent LNA and only
7,880 underwent both procedures simultaneously. Patients
with strongly positive DAT titers would have been treated for
VL without undergoing further LNA, and we found that
these are the patients in whom the LNA result was most likely
to be positive (adjusted odds ratio  28.3).
With regard to LNA specificity, microscopic demonstration
of parasites is 100% specific. Interestingly, we observed that
TABLE 1
Performance of lymph node aspiration and direct agglutination test in
patients with suspected VL at MSF–Holland VL treatment centers
in eastern Sudan, February 1998–August 2001*
Direct agglutination test
Total Titers  1:6,400 Titers < 1:6,400
Lymph node Positive 2,310 782 3,092
aspiration Negative 1,241 3,547 4,788
Total 3,551 4,329 7,880
*V L visceral leishmaniasis; MSF  Me ´decins Sans Frontie `res.
TABLE 2
Grades of parasite density in lymph node aspirates and the corre-
sponding titers of the direct agglutination test among patients sus-
pected of having primary VL seen at Me ´decins Sans Frontie `res–





Total Titers  1:400 Titers 1:800–1:3,200 Titers  1:6,400
Negative 2,126 1,421 1,241 4,788
Grade 1 66 249 372 687
Grade 2 54 242 793 1,089
Grade 3 27 98 621 746
Grade 4 8 31 334 373
Grade 5 3 4 155 162
Grade 6 0 0 35 35
Total 2,284 2,045 3,551 7,880
*V L visceral leishmaniasis. P < 0.0001 by chi-square test for trend.
LYMPH NODE ASPIRATION AND DIAGNOSIS OF VL 69125% (782 of 3,092) of our parasitologically confirmed VL
cases were missed by the DAT when a diagnostic cut-off titer
 1:6,400 was used. Most of these subjects (78.1%) had low
parasite densities in their LNAs, which suggested that a cut-
off titer  1:6,400 for the DAT is less sensitive in identifying
VL cases in the early or mild stages of disease, assuming this
shows a correlation with low parasite load.
We found a strong correlation between parasite density in
LNAs and the corresponding DAT titers in our 7,880 pa-
tients. This is in contrast to a previous study in 49 patients,
14
in which no correlation was found between DAT titers and
parasite load in splenic aspirates. The correlation between
DAT titers and parasite load in LNAs shown in this study
suggests that these diagnostic methods are complementary.
One estimate is that the sole use of parasitologic methods
could avert only 53% of deaths attributable to VL but that
combining the DAT and LNA would prevent 85% of mor-
tality attributable to VL.
15
We do not think that co-infection with human immunode-
ficiency virus (HIV) had much influence on our results. The
United Nations AIDS program estimated an HIV prevalence
rate of 1.9% (range  0.7–5.2%) for Sudanese adults 15–49
years of age by the end of 2001,
16 but accurate estimates for
other age groups were lacking. We also find it reassuring that
co-infection with HIV in east African patients does not ad-
versely affect the performance of the DAT, unlike the situa-
tion in southern Europe.
17,18
Our multivariate analysis indicated that VL is more likely
in those with a compatible illness if they are < 30 years of age,
male, and anemic. The difference observed between our two
treatment centers in eastern Sudan in terms of the likelihood
of obtaining a positive LNA result is probably due to a higher
level of VL endemicity in Um Elkheir.
We found only one important discrepancy in 50 patients
undergoing simultaneous LNA and SA at the end of VL
treatment. This probably represents a false-negative SA re-
sult, rather than a false-positive LNA result, because of the
significant number of parasites detected. Although there have
been reports of parasites in lymph nodes in patients with
PKDL, we did not find parasites in 20 such LNAs.
In conclusion, we found LNA to be a useful diagnostic tool
for VL in the Sudan. Parasitologic confirmation with LNA in
patients suspected of having VL with borderline DAT titers
(> 1:400 but < 1:6,400) is imperative. Performances of LNAs
and SAs were similar in assessing parasite clearance after
adequate treatment for VL. We also found no evidence of
parasites in LNAs obtained from patients with severe PKDL.
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TABLE 3
Multivariate analysis of predictors of a positive LNA in patients suspected of having primary VL seen at Me ´decins Sans Frontie `res–Holland
treatment centers in eastern Sudan from February 1998 through August 2001*
Characteristic Total Positive LNAs Adjusted odds ratio† 95% confidence interval P
Age group (years)
< 1 74 29 1.88 0.99–3.57 NS
1–4 1,240 517 2.38 1.76–3.21 < 0.0001
5–14 3,341 1,592 1.97 1.51–2.58 < 0.0001
15–29 2,780 1,087 1.42 1.08–1.86 < 0.02
30–44 1,196 327 1.16 0.86–1.56 NS
 45 614 114 1.00
Sex
Male 5,998 2,436 1.28 1.14–1.44 < 0.0001
Female 3,316 1,253 1.00
Hemoblobin level (g/dL)
< 6.0 1,038 433 2.68 2.18–3.31 < 0.0001
6.0–7.9 2,312 1,275 2.50 2.13–2.93 < 0.0001
8.0–9.9 2,737 1,175 1.73 1.49–2.01 < 0.0001
 10.0 3,060 758 1.00
Season
October–December 3,007 1,210 1.05 0.89–1.25 NS
January–March 3,142 1,301 0.89 0.75–1.06 NS
April–June 1,885 668 0.71 0.59–0.86 < 0.0002
July–September 1,286 512 1.00
Treatment center
Um Elkheir 4,670 2,112 2.62 2.32–2.97 < 0.0001
Kassab 4,650 1,579 1.00
DAT titer
 1:6,400 3,551 2,310 28.32 23.3–34.33 < 0.0001
1:800–1:3,200 2,045 624 6.12 5.02–7.46 < 0.0001
 1:400 2,284 158 1.00
* LNA  lymph node aspiration; VL  visceral leishmaniasis; NS  not significant (P > 0.05); DAT  direct agglutination titer.
† Adjusted for all other factors listed.
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